Cargando…

Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease

BACKGROUND: Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiquitous and often overlooked. We studied a novel chronic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Peabody, John W, Ganesan, Divya, Valdenor, Czarlota, Paculdo, David, Schrecker, Joshua, Westerfield, Christopher, Heltsley, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105436/
https://www.ncbi.nlm.nih.gov/pubmed/37061690
http://dx.doi.org/10.1186/s12875-023-02042-4
_version_ 1785026210488647680
author Peabody, John W
Ganesan, Divya
Valdenor, Czarlota
Paculdo, David
Schrecker, Joshua
Westerfield, Christopher
Heltsley, Rebecca
author_facet Peabody, John W
Ganesan, Divya
Valdenor, Czarlota
Paculdo, David
Schrecker, Joshua
Westerfield, Christopher
Heltsley, Rebecca
author_sort Peabody, John W
collection PubMed
description BACKGROUND: Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiquitous and often overlooked. We studied a novel chronic disease management (CDM) test to detect medication adherence and the presence and severity of DDIs. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of 236 primary care physicians using computer-based, simulated patients, measuring clinical care with and without access to the CDM test. The primary outcomes were whether use of the CDM test increased the accuracy of diagnoses and ordering better treatments and how effective the intervention materials were in getting participants to order the CDM test. RESULTS: Physicians given the CDM test results showed a + 13.2% improvement in their diagnosis and treatment quality-of-care scores (p < 0.001) in the NA patient cases and a + 13.6% improvement in the DDI cases (p < 0.001). The difference-in-difference calculations between the intervention and control groups were + 10.4% for NA and + 10.8% for DDI (p < 0.01 for both). After controlling for physician and practice co-factors, intervention, compared to control, was 50.4x more likely to recognize medication NA and 3.3x more likely to correctly treat it. Intervention was 26.9x more likely to identify the DDI and 15.7x more likely to stop/switch the interacting medication compared to control. We found no significant improvements for the disease progression patient cases. CONCLUSION: Distinguishing between nonadherence, drug-drug interactions, and disease progression is greatly improved using a reliable test, like the CDM test; improved diagnostic accuracy and treatment has the potential to improve patient quality of life, medication safety, clinical outcomes, and efficiency of health delivery. TRIAL REGISTRATION: clinicaltrials.gov (NCT05192590). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-023-02042-4.
format Online
Article
Text
id pubmed-10105436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101054362023-04-16 Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease Peabody, John W Ganesan, Divya Valdenor, Czarlota Paculdo, David Schrecker, Joshua Westerfield, Christopher Heltsley, Rebecca BMC Prim Care Research BACKGROUND: Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiquitous and often overlooked. We studied a novel chronic disease management (CDM) test to detect medication adherence and the presence and severity of DDIs. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of 236 primary care physicians using computer-based, simulated patients, measuring clinical care with and without access to the CDM test. The primary outcomes were whether use of the CDM test increased the accuracy of diagnoses and ordering better treatments and how effective the intervention materials were in getting participants to order the CDM test. RESULTS: Physicians given the CDM test results showed a + 13.2% improvement in their diagnosis and treatment quality-of-care scores (p < 0.001) in the NA patient cases and a + 13.6% improvement in the DDI cases (p < 0.001). The difference-in-difference calculations between the intervention and control groups were + 10.4% for NA and + 10.8% for DDI (p < 0.01 for both). After controlling for physician and practice co-factors, intervention, compared to control, was 50.4x more likely to recognize medication NA and 3.3x more likely to correctly treat it. Intervention was 26.9x more likely to identify the DDI and 15.7x more likely to stop/switch the interacting medication compared to control. We found no significant improvements for the disease progression patient cases. CONCLUSION: Distinguishing between nonadherence, drug-drug interactions, and disease progression is greatly improved using a reliable test, like the CDM test; improved diagnostic accuracy and treatment has the potential to improve patient quality of life, medication safety, clinical outcomes, and efficiency of health delivery. TRIAL REGISTRATION: clinicaltrials.gov (NCT05192590). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-023-02042-4. BioMed Central 2023-04-15 /pmc/articles/PMC10105436/ /pubmed/37061690 http://dx.doi.org/10.1186/s12875-023-02042-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Peabody, John W
Ganesan, Divya
Valdenor, Czarlota
Paculdo, David
Schrecker, Joshua
Westerfield, Christopher
Heltsley, Rebecca
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title_full Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title_fullStr Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title_full_unstemmed Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title_short Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
title_sort randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105436/
https://www.ncbi.nlm.nih.gov/pubmed/37061690
http://dx.doi.org/10.1186/s12875-023-02042-4
work_keys_str_mv AT peabodyjohnw randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT ganesandivya randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT valdenorczarlota randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT paculdodavid randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT schreckerjoshua randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT westerfieldchristopher randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease
AT heltsleyrebecca randomizedprospectivetrialtodetectanddistinguishbetweenmedicationnonadherencedrugdruginteractionsanddiseaseprogressioninchroniccardiometabolicdisease